Geron(NASDAQ) GERN

Current Price$1.44

Market Cap$930.21M

Since IPO (1996)-80%

5 Year+12%

1 Year+9%

1 Month+7%

Geron last closing stock price
Metric	Price	Date
Last close	USD 1.45	2026-07-23

Geron stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.11%	USD 1.42	2026-07-16
1 month	+7.41%	USD 1.35	2026-06-23
3 month	-3.33%	USD 1.50	2026-04-24
Year to date	+9.85%	USD 1.32	2025-12-31
1 year	+9.02%	USD 1.33	2025-07-23
3 year	-52.15%	USD 3.03	2023-07-24
5 year	+12.4%	USD 1.29	2021-07-23
Since inception	-79.6%	USD 7.11	1996-07-31

Geron Financials at a Glance

Market Cap

$930.21M

Revenue (TTM)

$196.12M

Net Income (TTM)

-$69.59M

EPS (TTM)

-$0.10

P/E Ratio

-13.90

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$1.44

Volume

3,289,531.69

Open

$1.45

Price

$1.44

Volume

3,289,531.69

Open

$1.45

Previous Close

$1.42

Daily Range

$1.41 - $1.46

52-Week Range

$1.04 - $2.01

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$1.44

Volume

3,289,531.69

Open

$1.45

Previous Close

$1.42

Daily Range

$1.41 - $1.46

52-Week Range

$1.04 - $2.01

Estimated Earnings Date

Aug 5, 2026

GERN News

Page 1

GERN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Geron

Geron helps people with blood cancer by making a new kind of medicine. This medicine lets the body create healthy blood cells again. It supports adults who have severe anemia and need regular blood transfusions.

The Fight Against Blood Cancer

RYTELO (imetelstat): A first-in-class telomerase inhibitor that targets blood cancers like lower-risk myelodysplastic syndromes, known as MDS.
Pipeline Programs: Clinical studies testing imetelstat for other conditions including myelofibrosis, which is bone marrow scarring, and leukemia.

Recent Milestones and Strategy

Launched RYTELO in the U.S. in June 2024 after receiving approval from the Food and Drug Administration.
Partnered with Tanner Pharma to provide global access to RYTELO through Named Patient Programs.
Received approval from the European Commission in March 2025 to market RYTELO in 27 European Union countries.
Completed enrollment for the IMpactMF Phase 3 clinical trial in September 2025 to evaluate patient survival.
Implemented a restructuring plan in December 2025 to reduce the workforce and lower total operating costs.

What Makes the Science Unique?

Geron uses Nobel Prize-winning science to stop the uncontrolled growth of cancer cells in the bone marrow. By blocking the telomerase enzyme, the treatment helps patients produce healthy cells and potentially changes the disease course.

Financial Performance at a Glance

Revenue reached $48 million in Q4 2025, up 1% from $47.5 million in Q4 2024.
Operating income was -$10.8 million in Q4 2025, improved 46.2% from -$20.1 million in Q4 2024.
Net loss reached $31.1 million in Q4 2025, worsened 22.8% from $25.4 million in Q4 2024.
Free cash flow hit -$22.1 million in Q4 2025, improved 49.6% from -$43.8 million in Q4 2024.
Market capitalization was $880.7 million in Q4 2025, down 61.5% from $2.3 billion in Q4 2024.

The Bottom Line

Geron has evolved from a research-focused biotech firm into a commercial company with a global footprint. Its growth depends on successfully selling its first approved drug while expanding its science to other blood cancers.

AI Generated • May 2, 2026

Industry

Biotechnology

Sector

Health Care

Employees

258

CEO

Harout Semerjian, MBA

Website

www.geron.com

Headquarters

Foster City, CA 94404, US

GERN Financials

Key Financial Metrics (TTM)

Gross Margin

86.59%

Operating Margin

-19.05%

Net Income Margin

-35.48%

Return on Equity

-28.90%

Return on Capital

-11.28%

Return on Assets

-13.03%

Earnings Yield

-7.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$930.21M

Shares Outstanding

641.52M

Volume

3.29M

Avg. Volume

12.84M

Financials (TTM)

Gross Profit

$169.81M

Operating Income

-$37.37M

EBITDA

-$36.95M

Operating Cash Flow

-$125.96M

Capital Expenditure

-$333.00K

Free Cash Flow

-$126.30M

Cash & ST Invst.

$314.29M

Total Debt

$251.84M

Geron Performance Analysis

Geron annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 596,000	-57.2%
2023	2023-12-31	USD 237,000	-60.2%
2024	2024-12-31	USD 76,994,000	32386.9%
2025	2025-12-31	USD 183,881,000	138.8%

Geron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	23.8%
Q3	2025-09-30	-3.7%
Q4	2025-12-31	1.7%
Q1	2026-03-31	8.0%

Geron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.37	5.1%
2023	2023-12-31	USD -0.32	-13.4%
2024	2024-12-31	USD -0.27	-16.3%
2025	2025-12-31	USD -0.13	-53.7%

Geron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	18.0%
Q3	2025-09-30	-12.2%
Q4	2025-12-31	-69.2%
Q1	2026-03-31	88.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$51.84M

+30.9%

Gross Profit

$50.15M

+30.6%

Gross Margin

96.74%

N/A

Market Cap

$930.21M

N/A

Market Cap/Employee

$3.61M

N/A

Employees

258

N/A

Net Income

-$3.64M

+81.6%

EBITDA

$3.83M

+133.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$314.29M

-20.8%

Total Debt

$251.84M

+106.8%

Accounts Receivable

$44.10M

+29.8%

Inventory

$0.00

-100.0%

Long Term Debt

$231.44M

+91.6%

Short Term Debt

$20.40M

+1979.2%

Return on Assets

-13.03%

N/A

Return on Invested Capital

-8.11%

N/A

Free Cash Flow

-$63.16M

-31.6%

Operating Cash Flow

-$62.91M

-31.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

REPLReplimune Group, Inc.

REPLReplimune Group, Inc.$9.70-7.27%

SVRASavara Inc.

SVRASavara Inc.$5.51-4.17%

ARVNArvinas, Inc.

ARVNArvinas, Inc.$8.03-1.11%

RZLTRezolute, Inc.

RZLTRezolute, Inc.$4.99-6.03%

VALNValneva SE

VALNValneva SE$4.78+0.00%

VIRVir Biotechnology, Inc.

VIRVir Biotechnology, Inc.$8.69-6.96%

AVBPArriVent BioPharma, Inc.

AVBPArriVent BioPharma, Inc.$31.73+0.60%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

TAT&T

TAT&T$24.13+0.05%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.00-0.03%

Questions About GERN

What is the current price of Geron?

Geron is trading at $1.42 per share.

What is the 52-week range for Geron?

Over the past 52 weeks, Geron has traded between $1.04 and $2.01.

How much debt does Geron have?

As of the most recent reporting period, Geron reported total debt of $251.84M.

How much cash does Geron have on hand?

Geron reported $70.78M in cash and cash equivalents in its most recent financial results.

What is Geron’s dividend yield?

Geron does not currently have a dividend yield.

Geron(NASDAQ) GERN

Geron Financials at a Glance

GERN News

Geron (GERN) Q2 Revenue Jumps 5,477%

Why Geron Stock Crept Higher Today

Why Geron Stock Is Plummeting Today

Is Geron Stock a Buy Following Its First New Drug Approval?

Why Shares of Geron Are Up 30% This Week

2 Top Healthcare Stocks to Buy Right Now

These 2 Nasdaq Biotechs Are Making Big Moves Wednesday

Why Geron's Shares Rose 14.78% on Wednesday

GERN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Geron

The Fight Against Blood Cancer

Recent Milestones and Strategy

What Makes the Science Unique?

Financial Performance at a Glance

The Bottom Line

GERN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Geron Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GERN

What is the current price of Geron?

What is the 52-week range for Geron?

How much debt does Geron have?

How much cash does Geron have on hand?

What is Geron’s dividend yield?

Premium Investing Services